Combination of Radiotherapy and Immunotherapy in Advanced Non-Small Cell Lung Cancer - PubMed
5 hours ago
- #Real-World Survival Data
- #Radiotherapy-Immunotherapy Combination
- #Non-Small Cell Lung Cancer
- Sequential iRT (immunotherapy and radiotherapy) shows longer survival than concurrent iRT in newly diagnosed advanced NSCLC, with a median OS of 20.3 months vs. 16.0 months.
- Chemotherapy is associated with longer survival in patients with newly diagnosed advanced NSCLC, while its benefit in refractory NSCLC is unclear.
- In refractory NSCLC, RT with ICI maintenance results in a numerically longer median OS (11.2 months vs. 6.7 months), though not statistically significant.